Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600513'
s Days Payable Range Over the Past 10 Years
Min: 82.79 Med: 107.73 Max: 134.72
Current: 91.05
During the past 13 years, Jiangsu Lianhuan Pharmaceutical Co's highest Days Payable was 134.72. The lowest was 82.79. And the median was 107.73.
SHSE:600513's Days Payable is ranked better than 50.38% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs SHSE:600513: 91.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Lianhuan Pharmaceutical Co Days Payable Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Lianhuan Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Lianhuan Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Lianhuan Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Jiangsu Lianhuan Pharmaceutical Co's Days Payable falls into.
Jiangsu Lianhuan Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Days Payable of 91.18 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. This is 15% below median its historical median of 107.73. Over the past decade, Jiangsu Lianhuan Pharmaceutical Co's Days Payable has ranged from 82.79 to 134.72. According to the industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #459 out of 925 companies in the Drug Manufacturers industry, placing it in the top 49.6%.
Is Jiangsu Lianhuan Pharmaceutical Co's Days Payable too high?
Jiangsu Lianhuan Pharmaceutical Co's current Days Payable of 91.18 is 15% below median its 10-year median of 107.73. Over the past 10 years, this metric has ranged from a low of 82.79 to a high of 134.72. The Drug Manufacturers industry median Days Payable is 90.38. Jiangsu Lianhuan Pharmaceutical Co's value of 91.18 is 0.9% above this industry median. Based on the distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #459 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #459 out of 925 companies for Days Payable. This puts Jiangsu Lianhuan Pharmaceutical Co in the upper half of its industry. The industry median Days Payable is 90.38. Jiangsu Lianhuan Pharmaceutical Co's value of 91.18 is 0.9% above this benchmark. Historically, Jiangsu Lianhuan Pharmaceutical Co's own Days Payable has ranged from 82.79 to 134.72 over the past decade. While the company's 10-year median is 107.73 vs. the industry median of 90.38, Jiangsu Lianhuan Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Lianhuan Pharmaceutical Co's current Days Payable of 91.18 is 0.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Lianhuan Pharmaceutical Co's current Days Payable is 91.18, which is 15% below median its own 10-year median of 107.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥13.72, compared to a current price of ¥15.42 — trading 12.4% above its estimated fair value. The current Days Payable is 91.18, which is 15% below median its 10-year median of 107.73 and 0.9% above the Drug Manufacturers industry median of 90.38. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Days Payable is 91.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥15.42 is trading 12.4% above its estimated GF Value™ of ¥13.72.
GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:600513:
Days Payable: 91.18 (15% below median its 10-year median of 107.73)
GF Value™: ¥13.72 vs. price of ¥15.42 (12.4% above fair value)
Industry Position: 0.9% above the Drug Manufacturers median (#459 of 925)
No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Lianhuan Pharmaceutical Co Business Description
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
65GF Score
Get the complete analysis for SHSE:600513
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600513 has been successfully added to your 
